Final Results Of a Phase I Study Of The Anti-CD22 Antibody-Drug Conjugate (ADC) DCDT2980S With Or Without Rituximab (RTX) In Patients (Pts) With Relapsed Or Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (NHL)

Autor:	Advani, Ranjana, Chen, Andy I., Lebovic, Daniel, Brunvand, Mark W., Goy, Andre, Chang, Julie E., Hochberg, Ephraim, Yalamanchili, Sreeni *, Kahn, Robert *, Lu, Dan *, Chai, Akiko *, Chu, Yu-Waye *, Cheson, Bruce D.
Zdroj:	In Blood 15 November 2013 122(21):4399-4399
Databáze:	ScienceDirect
Externí odkaz:	Zobrazit plný text záznamu